Autopsy report · NCT00994630

Biomarkers for Bipolar Disorder: Chaperones and Reticulum Endoplasmatic Stress Response CHAP´s Study

“fail to get funding”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Suspended: paused, and may or may not restart.
• 20 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Sponsor

University of Sao Paulo

Sponsor type

University, hospital or other

Conditions

Bipolar Disease Type I

Participants

20 (planned, not actual)

Sites

1

Countries

Brazil

Trials that died the same way

• Complementary/Integrative Medicine for Brain Cancer Patients
  “Unable to attain funding” (91% match in meaning)
• Intense Regulated Pulsed Light Vs Standard of Care for the Treatment of Meibomian Gland Dysfunction
  “Failed to gain funding” (89% match in meaning)
• Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients
  “Fail of applying funding” (88% match in meaning)
• Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
  “Insufficient funding” (84% match in meaning)
• Effects of Steroid Tapering on Functional Capacity and Neurocognition
  “Funding not obtained” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.